A randomized, open-label clinical trial to evaluate immunogenicity and safety of an indigenously developed DTwP-Hib tetravalent combination vaccine (Easyfour®-TT) with Quadrovax® in Indian infants

• Egile Nagusiak: Lalitendu Mohanty (Egilea), Sunil Sharma (Egilea), Beauty Behera (Egilea), Sachin Panwar (Egilea), Charu Paliwal (Egilea), Anit Singh (Egilea), Anu Gupta (Egilea), Deepak Chandra Chilkoti (Egilea)
• Formatua: Liburua
• Argitaratua: Taylor & Francis Group, 2017-09-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

An open-label, randomized, multi-center trial was conducted to compare the immunogenicity and safety of an indigenously developed tetravalent DTwP-Hib vaccine, Easyfour®-TT with a commercially available vaccine, Quadrovax®. A total of 244 infants in good health, aged 6-10 weeks, were randomized in a...